Loading...
Interrupting Anticoagulation in Patients With Nonvalvular Atrial Fibrillation
Three target-specific oral anticoagulants (TSOACs)—dabigatran, rivaroxaban, and apixaban—have been approved by the FDA to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; however, no agents are currently approved to reverse the anticoagulant effects o...
Na minha lista:
| Udgivet i: | P T |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MediMedia USA, Inc.
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4264672/ https://ncbi.nlm.nih.gov/pubmed/25516695 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|